Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Xiaoping Su"'
Autor:
Jovanka Gencel-Augusto, Xiaoping Su, Yuan Qi, Elizabeth M. Whitley, Vinod Pant, Shunbin Xiong, Vrutant Shah, Jerome Lin, Encarnacion Perez, Marta L. Fiorotto, Iqbal Mahmud, Abhinav K. Jain, Philip L. Lorenzi, Nicholas E. Navin, Ellen R. Richie, Guillermina Lozano
Publikováno v:
Cancer Discovery. 13:1230-1249
Cancer-related alterations of the p53 tetramerization domain (TD) abrogate wild-type (WT) p53 function. They result in a protein that preferentially forms monomers or dimers, which are also normal p53 states under basal cellular conditions. However,
Autor:
Emilly S. Villodre, Xiaoding Hu, Juhee Song, Kristen Gomez, Xiaoping Su, James Reuben, Naoto T. Ueno, Debu Tripathy, Savitri Krishnamurthy, Bisrat Debeb
Publikováno v:
Cancer Research. 83:P3-05
Background: Inflammatory breast cancer (IBC) is a rare and extremely aggressive form of breast cancer with an increased propensity to disseminate to distant organs such as the brain; indeed, a previous study reported that 37% of patients with HER2+ I
Autor:
Xiaofan Lu, Yann Vano, Alexandra Helleux, Xiaoping Su, Véronique Lindner, Guillaume Davidson, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Reza Elaidi, Eva Compérat, Virginie Verkarre, Chengming Sun, Christine Chevreau, Mostefa Bennamoun, Hervé Lang, Thibault Tricard, Wenxuan Cheng, Li Xu, Irwin Davidson, Fangrong Yan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stéphane Oudard, Gabriel G. Malouf
Publikováno v:
Clinical Cancer Research. 29:1279-1291
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with clear-cell renal cell carcinomas (ccRCC). Although analyses of transcriptome, genetic alterations, and the tumor microenvironment (TME) have shed light int
Autor:
Dhruv Chachad, Lalit R. Patel, Carlos Vera. Recio, Rasoul Pourebrahim, Elizabeth M. Whitley, Wenyi Wang, Xiaoping Su, An Xu, Dung-Fang Lee, Guillermina Lozano
Publikováno v:
Cancer Research.
Missense mutations in the DNA binding domain of p53 are characterized as structural or contact mutations based on their effect on the conformation of the protein. These mutations show gain-of-function activities, such as promoting increased metastati
Autor:
Guillermina Lozano, Ellen R. Richie, Nicholas E. Navin, Philip L. Lorenzi, Abhinav K. Jain, Iqbal Mahmud, Marta L. Fiorotto, Encarnacion Perez, Jerome Lin, Vrutant Shah, Shunbin Xiong, Vinod Pant, Elizabeth M. Whitley, Yuan Qi, Xiaoping Su, Jovanka Gencel-Augusto
Cancer-related alterations of the p53 tetramerization domain (TD) abrogate wild-type (WT) p53 function. They result in a protein that preferentially forms monomers or dimers, which are also normal p53 states under basal cellular conditions. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9976fcab245f95317df38198617cf8
https://doi.org/10.1158/2159-8290.c.6603197.v2
https://doi.org/10.1158/2159-8290.c.6603197.v2
Autor:
Guillermina Lozano, Ellen R. Richie, Nicholas E. Navin, Philip L. Lorenzi, Abhinav K. Jain, Iqbal Mahmud, Marta L. Fiorotto, Encarnacion Perez, Jerome Lin, Vrutant Shah, Shunbin Xiong, Vinod Pant, Elizabeth M. Whitley, Yuan Qi, Xiaoping Su, Jovanka Gencel-Augusto
Table S1 shows predicted off target sites for p53TD mutant mice. Table S2 shows upregulated PPAR target genes in p53AD vs p53-null. Table S3 shows ATAC-seq and RNA-seq congruent genes in p53AD vs p53 null. Table S4 shows p53half site analysis in PPAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b03b2a491efd58e37db58aff38c7ea7
https://doi.org/10.1158/2159-8290.22645274.v1
https://doi.org/10.1158/2159-8290.22645274.v1
Autor:
Ana M. Gonzalez-Angulo, Maureen T. Cronin, Gordon B. Mills, Philip J. Stephens, Aysegul Sahin, Xiaofeng Zheng, Ana M. Lluch, Octavio Burgues, Juan Antonio Barrera, Pilar Eroles, Xiaoping Su, Vincent A. Miller, Jeffrey S. Ross, Gary A. Palmer, Ying Wang, Jose A. Pérez-Fidalgo, Roman Yelensky, Jaime Ferrer-Lozano, Garrett M. Frampton, Funda Meric-Bernstam
XLSX - 13K, Table 1a. 182 genes across entire coding sequence Table 1b. 14 genes sequenced across selected introns.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2d9727bcf47464cd5cb8688a4fb4ed
https://doi.org/10.1158/1535-7163.22501149
https://doi.org/10.1158/1535-7163.22501149
Autor:
Ana M. Gonzalez-Angulo, Maureen T. Cronin, Gordon B. Mills, Philip J. Stephens, Aysegul Sahin, Xiaofeng Zheng, Ana M. Lluch, Octavio Burgues, Juan Antonio Barrera, Pilar Eroles, Xiaoping Su, Vincent A. Miller, Jeffrey S. Ross, Gary A. Palmer, Ying Wang, Jose A. Pérez-Fidalgo, Roman Yelensky, Jaime Ferrer-Lozano, Garrett M. Frampton, Funda Meric-Bernstam
XLSX - 22K, Substitution, insertion and deletion mutations/large structural alterations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a7d2f6f502abe9e58c45e4ddef4ef0
https://doi.org/10.1158/1535-7163.22501155
https://doi.org/10.1158/1535-7163.22501155
Autor:
Gheath Alatrash, Jeffrey J. Molldrem, Jennifer K. Litton, Padmanee Sharma, Patrick Hwu, Michael Curran, Akhil Chawla, Argun Akcakanat, Ana M. Gonzalez-Angulo, Ying Wang, Xiaoping Su, Susan Harrington, Yun Wu, Na Qiao, Funda Meric-Bernstam, Anne V. Philips, Elizabeth A. Mittendorf
Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::948bcf525b18d256d5acec0434a585ae
https://doi.org/10.1158/2326-6066.c.6548291.v1
https://doi.org/10.1158/2326-6066.c.6548291.v1
Autor:
Ana M. Gonzalez-Angulo, Maureen T. Cronin, Gordon B. Mills, Philip J. Stephens, Aysegul Sahin, Xiaofeng Zheng, Ana M. Lluch, Octavio Burgues, Juan Antonio Barrera, Pilar Eroles, Xiaoping Su, Vincent A. Miller, Jeffrey S. Ross, Gary A. Palmer, Ying Wang, Jose A. Pérez-Fidalgo, Roman Yelensky, Jaime Ferrer-Lozano, Garrett M. Frampton, Funda Meric-Bernstam
PDF - 138K, Adjuvant systemic treatments.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecccb80dbcbe304de2821eac6a76bc9
https://doi.org/10.1158/1535-7163.22501143.v1
https://doi.org/10.1158/1535-7163.22501143.v1